Jim Cramer in a latest program on CNBC urged investors to start accepting the reality of the new economic system under ...

President Trump wants to bring pharmaceutical manufacturing back to the United States. Experts warn that tariffs could result ...

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

Both weekend warriors and steady exercisers had a significantly lower risk of premature death compared to inactive peoples, ...

Lawsuits against pharmacies in seven states aim to protect its flagship Mounjaro and Zepbound medications | Growing ...

Lawsuits against pharmacies in seven states aim to protect its flagship Mounjaro and Zepbound medications | Growing ...

Hims & Hers stirred the weight-loss waters by announcing it now offers prescriptions for Zepbound, Eli Lilly’s premium GLP-1 ...